Print this page
-
R1979-HM-1333: An Open-label, Multi-center Phase I Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 bispecific Monoclonal Antibody, in Patients with CD20+ B-cell Malignancies Previously Treated with CD20 Directed Antibody Therapy.
Protocol: 011411Principal Investigator:
- Rajat Bannerji Dr. (Rutgers University)
Applicable Disease Sites: Lymphoid Leukemia
Non-Hodgkin's Lymphoma -
A Phase Ib, Open-Label, Dose-Escalation, Multicenter Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Glofitamab Following Obinutuzumab Pretreatment In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012107Principal Investigator:
- Rajat Bannerji Dr. (Rutgers University)
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma.
Protocol: 011909Principal Investigator:
- Rajat Bannerji Dr. (Rutgers University)
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies.
Protocol: 012109Principal Investigator:
- Rajat Bannerji Dr. (Rutgers University)
Applicable Disease Sites: Non-Hodgkin's Lymphoma
Multiple Myeloma
Hodgkin's Lymphoma -
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Protocol: 012007Principal Investigator:
- Rajat Bannerji Dr. (Rutgers University)
Applicable Disease Sites: Non-Hodgkin's Lymphoma
